Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | -15.79% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.44 | N/A | -15.79% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the market conditions. They highlighted their commitment to innovation and long-term strategies.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term setbacks.
The earnings report indicates that 10X Genomics is facing challenges, as reflected in the EPS miss. However, the stock rose by 4.53%, suggesting that investors may be optimistic about the company's long-term potential despite current difficulties. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023